Drug Eluting Balloons Catheters Market Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications
Discover trends, market shifts, and competitive outlooks for the drug eluting balloons catheters industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Drug Eluting Balloons Catheters Market From 2025 To 2029?
The market for drug eluting balloons catheters has seen a swift expansion in recent times. The market size is projected to increase from $1.43 billion in 2024 to $1.66 billion in 2025, with a compound annual growth rate (CAGR) of 16.0%. This growth during the historic period results from the rise in respiratory ailments, benefits compared to conventional inhalers, the inclination of patients towards dpis, government-led health initiatives focusing on respiratory health, strategic alliances and partnerships, progress in drug formulations, along with an increasing aged population.
In the coming years, the drug eluting balloons catheters market size is projected to witness significant growth, escalating to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 12.0%. The growth during the forecast period is primarily due to the ongoing rise in respiratory disorders, growing elderly population, enhanced awareness and education, expanding market in emerging economies, personalized drug formulations, regulatory backing and adherence, as well as innovations in packaging and design. Key trends emerging during the forecast period encompass smart inhalers with connectivity, shift towards inhalers triggered by breath, attention on the needs of pediatric and geriatric patients, delivery of biologics, and environment-friendly inhaler designs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13429&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Drug Eluting Balloons Catheters Market?
The upward trend in peripheral and cardiovascular diseases is anticipated to fuel the expansion of the drug-eluting balloon catheter market. Cardiovascular disorders, denoting a variety of conditions impacting the heart and circulatory system, along with peripheral artery disease, which pertains to the narrowing of arteries that primarily hinder blood flow to arms or legs, are gaining prominence. Drug-eluting balloon catheters, which are a treatment method for coronary artery disease that employs an angioplasty balloon smeared with an anti-proliferative agent producing an anti-restenotic effect within the vessel, are becoming increasingly important. As an example, the Centers for Disease Control and Prevention reported that, in 2022, heart disease accounted for the deaths of 702,880 individuals, signifying 1 in every 5 deaths. About 805,000 people in America have a heart attack each year, including 605,000 experiencing their first heart attack along with 200,000 who have prior experience of it. Hence, the rising occurrence of peripheral and cardiovascular diseases is promoting the drug-eluting balloon catheter market’s growth.
Drug Eluting Balloons Catheters Market Driver: Growth of Drug-Eluting Balloon Catheter Market Fostered by Demand for Minimally Invasive Procedures
Which Primary Segments of the Drug Eluting Balloons Catheters Market Are Driving Growth and Industry Transformations?
The drug eluting balloons catheters market covered in this report is segmented –
1) By Product: Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters
2) By Drug: Paclitaxel, Sirolimus, Other Drugs
3) By Raw Material: Nylon, Polyurethane, Other Raw Materials
4) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Catheterization Laboratories
Subsegments:
1) By Coronary Artery Disease: Drug-Eluting Balloon Catheters, Plain Balloon Catheters
2) By Peripheral Vascular Disease: Drug-Eluting Balloon Catheters, Angioplasty Balloon Catheters
3) By Angioplasty Balloon Catheters: Drug-Eluting Angioplasty Balloon Catheters
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13429&type=smp
Which Regions Are Key Players in the Growth of the Drug Eluting Balloons Catheters Market?
North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Drug Eluting Balloons Catheters Market?
Prominent organizations in the drug-eluting balloon catheter market are intensifying their efforts to fabricate state-of-the-art products by incorporating advanced technologies to secure a competitive lead. For instance, Boston Scientific Corporation, an American biomedical and biotechnology engineering company and transnational producer of medical appliances, disclosed in March 2024 that they had secured the approval of the U.S. Food and Drug Administration (FDA) for their acclaimed AGENT Drug-Coated Balloon (DCB). AGENT DCB is groundbreaking as the first drug-coated coronary balloon permitted in the U.S. to address in-stent restenosis (ISR), a condition in which a stented vessel is obstructed by plaque or scar tissue. This product is distinctive due to its paclitaxel coating, which delivers a healing dose to the vessel wall, thereby mitigating the recurrence of ISR without requiring extra stents or radiation. In clinical trials, it demonstrated a 49% reduction in the risk of heart attacks at the focus site and indicated minimal occurrence of adverse incidents.
View the full report here:
What Parameters Are Used to Define the Drug Eluting Balloons Catheters Market?
A drug-eluting balloon catheter is a medical device used to treat coronary artery disease by percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon coated with an anti-proliferative drug that is released into the vessel wall during inflation, which helps to prevent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13429
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
